Dosage Form Proportionality of Opicapone To-Be-Marketed Formulation

NCT02305329 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Epilepsy

Interventions

DRUG: BIA 9-1067

Sponsor

Bial - Portela C S.A.